GM-SR2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glycemic control. This synergistic combination targets multiple pathophysiological defects of type 2 diabetes, making it effective in patients inadequately controlled by diet, exercise, and monotherapy. GM-SR2 Tablet should be used as part of a comprehensive diabetes management plan including diet and lifestyle modifications. It is contraindicated in patients with known hypersensitivity to either component, renal or hepatic impairment, metabolic acidosis, or diabetic ketoacidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, with a low risk of hypoglycemia primarily attributable to Glimepiride. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. GM-SR2 Tablet offers a convenient and effective option for optimizing glycemic control in type 2 diabetes mellitus.